Restricted accessResearch articleFirst published online 2012-09
Short Communication: Increased Expression of Secretory Leukocyte Protease Inhibitor in Oral Mucosa of Colombian HIV Type 1-Exposed Seronegative Individuals
The exposure to human immunodeficiency virus type 1 (HIV-1) does not always result in infection. Indeed, there are individuals who have been repeatedly exposed to HIV-1 but do not exhibit clinical or serological evidence of infection; they are known as HIV-exposed seronegative individuals (HESN). To determine if secretory leukocyte protease inhibitor (SLPI), a soluble factor secreted by epithelial cells lining mucosal surfaces that showed anti-HIV activity in vitro, was associated with natural resistance to HIV infection, we measured by real time RT-PCR the expression of SLPI in oral mucosa of a cohort of Colombian HESN, in chronically HIV-1-infected individuals and in healthy controls. The HESN expressed significantly higher levels of SLPI mRNA than healthy controls (p=0.033) and chronically infected subjects (p=0.011). These findings suggest an association between SLPI expression and the natural resistance to HIV-1 infection exhibited by our HESN cohort.
Get full access to this article
View all access options for this article.
References
1.
PiacentiniL, FeniziaC, NaddeoV, ClericiM. Not just sheer luck! Immune correlates of protection against Hiv-1 infection. Vaccine, 2008; 26:3002–3007.
2.
MannJM, TarantolaDJ. HIV 1998: The global picture. Sci Am, 1998; 279:82–83.
3.
ZapataWRB, WeberJ, EstradaH, Quiñones-MateuM, ZimermmanP, LedermanM, RugelesM. Increased levels of human beta-defensins mRNA in sexually Hiv-1 exposed but uninfected individuals. Current HIV Res, 2008; 6.
4.
SallenaveJM. Secretory leukocyte protease inhibitor and elafin/trappin-2: Versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol, 2010; 42:635–643.
5.
ZapataW, MontoyaCJ, RugelesMT. [Soluble factors with inhibitory activity against type 1 human immunodeficiency virus]Biomedica, 2006; 26:451–466.
6.
FarquharC, VanCottTC, Mbori-NgachaDA, HoraniL, BosireRK, KreissJK, RichardsonBA, John-StewartGC. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis, 2002; 186:1173–1176.
7.
JanaNK, GrayLR, ShugarsDC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: A role for SLPI in innate mucosal immunity. J Virol, 2005; 79:6432–6440.
8.
McNeelyTB, DealyM, DrippsDJ, OrensteinJM, EisenbergSP, WahlSM. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest, 1995; 96:456–464.
9.
McNeelyTB, ShugarsDC, RosendahlM, TuckerC, EisenbergSP, WahlSM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood, 1997; 90:1141–1149.
10.
GohWC, MarkeeJ, AkridgeRE, MeldorfM, MuseyL, KarchmerT, KroneM, CollierA, CoreyL, EmermanM, McElrathMJ. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis, 1999; 179:548–557.
HasselrotK, BrattG, DuvefeltK, HirbodT, SandstromE, BrolidenK. HIV-1 exposed uninfected men who have sex with men have increased levels of salivary CC-chemokines associated with sexual behavior. AIDS, 2010; 24:1569–1575.
13.
HirbodT, ReichardC, HasselrotK, SoderlundJ, KimaniJ, BwayoJJ, PlummerF, KaulR, BrolidenK. HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. Curr HIV Res, 2008; 6:28–33.
14.
NovakRM, DonovalBA, GrahamPJ, BoksaLA, SpearG, HershowRC, ChenHY, LandayA. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol, 2007; 14:1102–1107.
15.
PillayK, CoutsoudisA, Agadzi-NaqviAK, KuhnL, CoovadiaHM, JanoffEN. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis, 2001; 183:653–656.
16.
ConaldiPG, BianconeL, BottelliA, Wade-EvansA, RacusenLC, BoccellinoM, OrlandiV, SerraC, CamussiG, TonioloA. HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and fas upregulation. J Clin Invest, 1998; 102:2041–2049.
17.
QureshiMN, BarrCE, SeshammaT, ReidyJ, PomerantzRJ, BagasraO. Infection of oral mucosal cells by human immunodeficiency virus type 1 in seropositive persons. J Infect Dis, 1995; 171:190–193.
18.
RayPE, LiuXH, HenryD, DyeL3rd, XuL, OrensteinJM, SchuztbankTE. Infection of human primary renal epithelial cells with HIV-1 from children with HIV-associated nephropathy. Kidney Int, 1998; 53:1217–1229.
19.
TonioloA, SerraC, ConaldiPG, BasoloF, FalconeV, DoleiA. Productive HIV-1 infection of normal human mammary epithelial cells. AIDS, 1995; 9:859–866.
20.
RyzhovaEV, VosRM, AlbrightAV, HarristAV, HarveyT, Gonzalez-ScaranoF. Annexin 2: A novel human immunodeficiency virus type 1 gag binding protein involved in replication in monocyte-derived macrophages. J Virol, 2006; 80:2694–2704.
21.
MaG, Greenwell-WildT, LeiK, JinW, SwisherJ, HardegenN, WildCT, WahlSM. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med, 2004; 200:1337–1346.
